INMB Live signals | Maximize Profits with Getagraph.com

BUY 94092 min ago

@ $14.06

Issued: 14 Feb 2024 @ 15:50

Return: -40.47%

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease...

Stats
Today's Volume	68 767.00
Average Volume	87 380.00
Market Cap	152.36M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.540 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.01
ATR14	$0.0440 (0.53%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-10	Juda Scott	Buy	7 000	Common Stock
2023-07-12	Schroeder Timothy J	Sell	10 000	Common Stock
2023-03-17	Moss David J	Buy	2 500	Common Stock
2023-02-16	Tesi Raymond Joseph	Buy	160 000	Option (right to buy)
2023-02-16	Juda Scott	Buy	35 000	Option (right to buy)

INSIDER POWER
94.48
Last 100 transactions
Buy: 4 257 822 \| Sell: 701 956

Volume Correlation

Long: 0.01 (neutral)

Short: 0.86 (strong)

Signal:(51.198) Same movement expected

INmune Bio Inc Correlation

10 Most Positive Correlations
ECPG	0.878
FIVN	0.859
TREE	0.855
IPDN	0.844
PIRS	0.843
CWBR	0.833
LCFY	0.83
STX	0.828
NXST	0.828
PALT	0.826

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

INmune Bio Inc Correlation - Currency/Commodity

-0.32
( neutral )

-0.14
( neutral )

0.00
( neutral )

0.26
( neutral )

-0.17
( neutral )

-0.41
( neutral )

INmune Bio Inc Financials

Annual	2023
Revenue:	$155 000
Gross Profit:	$155 000 (100.00 %)
EPS:	$-1.670

Q4	2023
Revenue:	$28 000.00
Gross Profit:	$28 000.00 (100.00 %)
EPS:	$-0.470

Q3	2023
Revenue:	$43 000.00
Gross Profit:	$43 000.00 (100.00 %)
EPS:	$-0.480

Q2	2023
Revenue:	$46 000.00
Gross Profit:	$46 000.00 (100.00 %)
EPS:	$-0.360

Financial Reports:

No articles found.

INmune Bio Inc

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.